{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:35:51Z","timestamp":1765888551223,"version":"3.41.2"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570884, 81770961"],"award-info":[{"award-number":["81570884, 81770961"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>As angiogenesis is an essential step in tumor growth and metastasis, the tyrosine kinase inhibitor (TKI) apatinib has become a revolutionary anticancer therapy across various malignancies. However, its efficiency and safety in Merkel cell carcinoma (MCC) are uncertain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>The current study described the case of a 91-year-old man who presented with a 3.2 \u00d7 3.0 \u00d7 2.2\u00a0cm rapidly growing, solitary tumor of the right lower eyelid. It was diagnosed as MCC pathologically. Twenty-seven days after the surgery, the patient returned to the hospital with recurrent MCC. Apatinib was then administered to this patient. The patient had a complete response (CR) to apatinib after 4.4 months of targeted therapy. Twenty-seven months of progression-free survival (PFS) was achieved with controllable treatment-related adverse events (AEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Treatment with apatinib demonstrated clinical benefit in our patient with recurrent MCC, highlighting its potential utility in other MCC patients. Further clinical trials are needed to determine the efficacy and safety of apatinib in MCC patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.625360","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T05:24:55Z","timestamp":1614749095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Yiyi","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renbing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejca.2016.10.022","article-title":"Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs","volume":"71","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17077","DOI":"10.1038\/nrdp.2017.77","article-title":"Merkel cell carcinoma","volume":"3","author":"Becker","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.11.020","article-title":"Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features","volume":"58","author":"Heath","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2017.10.028","article-title":"Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics","volume":"78","author":"Paulson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.056","article-title":"Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system","volume":"63","author":"Lemos","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0055","article-title":"Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Bichakjian","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S97235","article-title":"Apatinib for molecular targeted therapy in tumor","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2779-3","article-title":"Merkel cell carcinoma: 30-year experience from a single institution","volume":"20","author":"Santamaria-Barria","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.04.061","article-title":"Merkel cell carcinoma: 27-year experience at the Peter MacCallum Cancer Centre","volume":"80","author":"Hui","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.815","article-title":"Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma","volume":"5","author":"Iyer","year":"2016","journal-title":"Cancer Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19218","article-title":"Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe","volume":"8","author":"Becker","year":"2017","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0187","article-title":"Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA","volume":"13","author":"Cowey","year":"2017","journal-title":"Future Oncol (London England)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial","volume":"4","author":"D\u2019Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/modpathol.3800717","article-title":"Expression profiles associated with aggressive behavior in Merkel cell carcinoma","volume":"20","author":"Fern\u00e1ndez-Figueras","year":"2007","journal-title":"Mod Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2008.63","article-title":"Expression of VEGF-A\/C, VEGF-R2, PDGF-alpha\/beta, c-kit, EGFR, Her-2\/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma","volume":"21","author":"Brunner","year":"2008","journal-title":"Mod Pathol"},{"key":"B17","article-title":"Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma","volume":"27","author":"Kukko","year":"2007","journal-title":"Anticancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.029","article-title":"VEGF-A Inhibition as a Potential Therapeutic Approach in Merkel Cell Carcinoma","volume":"139","author":"Kervarrec","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0552","article-title":"Cabozantinib in Patients with Advanced Merkel Cell Carcinoma","volume":"23","author":"Rabinowits","year":"2018","journal-title":"Oncologist"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1200\/JCO.2009.21.8149","article-title":"Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma","volume":"27","author":"Davids","year":"2009","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.908649","article-title":"Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients","volume":"19","author":"Tarabadkar","year":"2018","journal-title":"Am J Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.01.014","article-title":"Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer","volume":"372","author":"Roviello","year":"2016","journal-title":"Cancer Lett"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.625360\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T05:24:58Z","timestamp":1614749098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.625360\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":22,"alternative-id":["10.3389\/fonc.2021.625360"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.625360","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,3,3]]},"article-number":"625360"}}